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Summary
Murine plasmacytomas show a striking dependence on interleukin 6 (IL6) for their growth in
vitro. Here, we present evidence suggesting that IL6 also plays an essential role in the in vivo
development of these tumors. This conclusion is based on the finding that the tumorigenicity
of an IL-6-dependent plasmacytoma cell line was increased -100-fold on transfection with an
IL-6 expression vector, whereas it was inhibited in animals treated with monoclonal antibodies
capable of blocking the binding of IL6 to its receptor. Injection of these antibodies 1 d before
tumor challenge protected >50% ofthe mice and retarded tumor growth in all animals. Tumors
arising in antibody-treated mice retained their 11,6 dependence in vitro, suggesting that the level
of protection could be improved if stronger IL6 antagonists were available.
I
t is now well established that IL6 is a critical factor for
the in vitro growth and survival of mouse plasmacytomas
(1, 2), and there is increasing support for the idea that it plays
an important role in the in vitro proliferation of human my-
elomas as well (3-6). The notion that IL-6 may also be of
importance for the in vivo growth of these tumors is sup-
ported by the following observations: (a) pristane-induced
granulomas, which produce large amounts of IL6 (1), are
critical not only for induction (7) but also for early trans-
plantation of mouse plasmacytomas (8) ; (b) overexpression
of IL6 in transgenic mice, although not sufficient to cause
the development of plasma cell tumors, induces strong plas-
macytosis (9); and (c) transfection with IL6 cDNA was re-
cently shown to increase the tumorigenicity of an 11,6-
dependent B cell hybridoma (10). While none ofthese findings
formally proves that IL6 is required for the in vivo growth
of plasmarytomas, they clearly call for a direct evaluation of
this possibility.
In the present report, we addressed this question by ex-
amining whether the tumorigenicity of a mouse plasmacy-
toma couldbe increased by transfection with an IL6 cDNA
and, more importantly, whether it could be inhibited by ad-
ministration ofantibodies directed against IL6 or against its
receptor.
Plasmid Construction.
￿
A mouse 11,6 cDNA fragment of 827 by
was isolated from clone pHP1B5 (11) by digestion with EcoRI and
DraI. This fragment, which contains the entire coding sequence
of11,6 but lacks-250 by at the 3' end of the gene, was subdoned
into the Sall site of plasmid pBMGneo (12). Northernblot analysis
was performed as described (11) using 32P-labeled mIL6 cDNA.
Transfection ofPlasmacytoma Cells with 11,6 cDNA. ' IL6-depen-
dent T1033C2 plasmacytoma cells were transfected by, electropora-
tion, and transfectants containing the IIr6 expression vector were
selected in G418. This population, terrkred TB6D2, secreted IL6
(-500 pg/106 cells/24 h, as measured; in the 7TD1 assay), and
could be cloned in the absence of exogenous IL6. A clone desig-
nated TB6D2.M was selected for further study. A control group
ofcells was transfected with the same plasmid containing the IL6
cDNA cloned in missense orientation. As expected, this popula-
tion, T136D1, remained 11,6 dependent. TB6D1 cells were cloned
in the presence ofIL6, and a clone termed TB6D1.M was selected
for further study. Northern blot analysis revealed the presence of
11,6 message in T136D2 but not in TB6D1 cells.
Antibodies.
￿
mAb 6134 is a neutralizing anti-11,6 IgGI antibody
of rat origin (13). Antibody 15A7 is a rat IgG2b that is directed
against a cell surface component ofIL6 receptor-positive cells and
blocks IL6 binding. The derivationand characteristics of this anti-
body will be described elsewhere (P. Coulie et al., manuscript in
preparation). Control rat antibodiesincluded Lo-DNP1(IgG1 anti-
DNP), Lo-DNP57 (IgG2b anti-DNP) (both gifts ofDr. H. Bazin,
Unit of Experimental Immunology, University of Louvain), and
2135 (IgG1 anti-mouse IgGI). Hybridomas were grown in pristane-
primed BALB/c nu/nu mice, and the asciticfluidwas collected under
sterile conditions. To avoid contamination with LPS, the ascites
were mostly used without further purification. For some experi-
ments, however, antibody 15A7 was purified by affinity chroma-
tography on mouse anti-rat rc-Sepharose (antibody MARKI given
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BALB/c mice were injected intraperitoneally with the indicated cell
doses and tumor development was followed over a 110-d period .
Median survival time is indicated in parentheses and is given for
tumor-bearing animals .
by Dr. H . Bazin) . F(ab')2 fragments were prepared from the
purified antibody by overnight digestion with pepsin at 37°C in
0.1 M acetate buffer, pH 4.2 . Under these conditions, digestion
was complete as verified by gel filtration on a Superose-12 FPLC
column .
Increased Tumorigenicity ofIL6producing Plasmacytoma Cells.
The influence of 11,6 on plasmarytoma cell growth in vivo
DAYS
Figure 1 .
￿
Inhibition of T1033C2 plasmacytoma growth in mice
treated with anti-11,6 or anti-II,6R antibodies before tumor challenge .
BALB/c mice were given a 1-ml subcutaneous injection of mono-
clonal rat antibodies in the back 24 h before intraperitoneal challenge
with 106 T1033C2 cells . Antibodies, administered in the form of as-
citic fluid obtained in nude mice, included control anti-DNP anti-
bodies Lo-DNP1 (IgGI; eight mice) (A) and Lo-DNP57 (IgG2b ;
seven mice) (Q), anti-IL6 antibody 6B4 (IgGI; 24 mice) (A), and
anti-IIL6R antibody 15A7 (IgG2b ; 23 mice) (/) . Additional controls
were injected with saline (31 mice) (O) .
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was examined in normal BALB/c mice using T1033C2 cells
transfected with an IL -6cDNA expression construct . All mice
injected intraperitoneally with 3 x 104 11,6-producing cells
(TB6D2.M) developed a tumor and died in 40 d . By con-
trast, in mice injected with the same number ofI1,6-dependent
cells, transfected with a missense construct (TB6D1.M), not
a single tumor arose, even after 110 d, when the experiment
was terminated . A high tumor incidence could nevertheless
be obtained with TB6D1.M cells, but only after injection
of 100-fold higher cell doses (Table 1) . In addition, evenwhen
TB6D1.M tumors developed, their growth rate was consider-
ably slower than that of the autonomous cells .
These differences could not be ascribed to intrinsic changes
in the growth rate of the cells because doubling times mea-
sured in vitro in the presence of saturating IL6 were of the
same order for both types of transfectants (10.2 h for TB6D1.M
and12 h forTB6D2.M) . They were also not due to the selec-
tion of unrepresentative clones because similar results were
obtained with the uncloned transfectant populations . More-
over, the increased mortality of mice injected with IL-6-
sufficient plasmacytoma cells did not result from a toxic effect
of IL-6 on the host because P815 mastocytoma cells trans-
fected with the 11,6-encoding plasmid and secreting amounts
of IL-6 higher than those produced byTB6D2.M (i .e ., 3,000
pg/ml/24 h/106 cells) did not show increased tumorige-
nicity. It therefore appears that the increased tumorigenicity
of T1033C2 cells producing IL-6 is a direct consequence of
the plasmarytoma growth factor activity of the cytokine . These
observations, which extend the findings reported by Tohyama
et al . (10) for an IL6-dependent B cell hybridoma, prove that
the plasmacytoma growth-promoting activity displayed by
IL-6 in vitro is not a culture artifact .
Inhibition of Plasmacytoma Growth In Vivo by Antibodies
Blocking the Action ofII,6. The increased tumorigenicity of
IL-6-producing T1033C2 cells does not prove that T1033C2
cells actually require IL6 for growth in vivo . To test this hy-
pothesis, we examined whether antibodies capable of neu-
tralizing the plasmacytoma growth factor activity of IL-6 in
vitro would inhibit tumor formation by IL-6-dependent
T1033C2 cells. We used two rat mAbs : one, termed 6B4,
that is directed against IL-6 (13), and one, termed 15A7, that
is directed against the 11,6 receptor, in as much as it binds
to IL6R-positive cells and competes with IL-6 for binding.
The antibodies were administered subcutaneously 24 h be-
fore intraperitoneal challenge with a tumorigenic dose of IL-
6-dependent plasmarytoma T1033C2 . Data pooled from a
series of experiments are shown in Fig. 1 . In mice injected
withmedium or with isotype-matched control ascites, tumor
incidence was >95% with a median survival time of 25-29 d.
By contrast, in the group of mice treated with antibody 6B4,
50% of the animals were protected, and the remainder had
a median survival time of38 d. When the animals were treated
with antibody 15A7, the protection rate was -60%, and the
median survival time of tumor-bearing animals was prolonged
to 40 d . This level of protection was obtained with 1-1.5
ml of ascites (equivalent to 0.5-3 mg of antibodies) .
The results described above indicate that the IL6 depen-
dence ofplasmacytomas T1033C2 is not exclusively an in vitro
Dose of
tumor cells
Tumor
IL-6-dependent cells
(TB6D1.M)
incidence
IL-6-producing cells
(TB6D2.M)
d d
10, 7/9 (39) 9/9 (16)
3 x 10 5 3/9 (41) 9/9 (20)
10 , 2/9 (41) 9/9 (20)
3 x 10 4 0/9 9/9 (26)
104 0/9 8/9 (30)Table 2.
￿
IL-6 Dependence of T1033C2 Tumors Arising in
Mice Treated with Anti-IL-6 Antibody
Cells were recovered from two tumors that arose in BALB/c mice
injected with 106 T1033C2 cells after treatment with anti-IL-6 anti-
body 6B4 . Cells were cultured without added IL-6 at an initial con-
centration of 3 x 105 cells/ml in the presence of the indicated
antibodies (10 ttg/ml), and cell growth was evaluated after 4 and
5 d for tumors D and E, respectively . Additional cultures were sup-
plemented with 5 ng/ml of rIL-6 .
phenomenon . They do not, however, rule out the possibility
that IL-6 acts only during a short period of time required
by the cell to adapt from in vitro to in vivo conditions. To
address this question, antibodies were administered 2wk after
tumor challenge, at a time when visible tumors had already
developed. Under these conditions, antibody 15A7 was found
to induce partial necrosis of some tumors. However, com-
plete remissions were never observed, although the treatment
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